On the basis of the results that the growth-inhibitory effects of statins in combination with dasatinib against CML cells were BCR-ABL mutation-independent, statins may also benefit the treatment of these diseases. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.